Gianpiero Martone, DO
Child & Adolescent Psychiatry · Erie, PANPI 1174936504
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $957 and has fallen 78.6% since, to $205 in 2021.
Across 31 payments — averaging $47.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ironshore Pharmaceuticals Inc.$296
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$274
- Sunovion Pharmaceuticals Inc.$192
- Alkermes, Inc.$178
- Teva Pharmaceuticals USA, Inc.$148
- Otsuka America Pharmaceutical, Inc.$131
- plus $267 from 6 others
What the payments were for
- Food & beverage$1,486100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ironshore Pharmaceuticals Inc. | 5 | $296 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $274 |
| Sunovion Pharmaceuticals Inc. | 2 | $192 |
| Alkermes, Inc. | 4 | $178 |
| Teva Pharmaceuticals USA, Inc. | 3 | $148 |
| Otsuka America Pharmaceutical, Inc. | 2 | $131 |
| Johnson & Johnson | 3 | $110 |
| Supernus Pharmaceuticals, Inc. | 1 | $64 |
| Avanir Pharmaceuticals, Inc. | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Indivior Inc. | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$489
- Jornay PM 20mg capsules (Bottle of 100)$258
- LATUDA$125
- ARISTADA INITIO$122
- AUSTEDO$119
- REXULTI$113
- CAPLYTA$100
How this compares
$1,486 in reported general payments places this provider in the 80th percentile of 200 child & adolescent psychiatry providers in Pennsylvania.
See all child & adolescent psychiatry providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 16 | $1,180 |
| Clonazepam | 32 | $223 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Erie
- Dennis BorczonErie$120K
- Robert WilsonErie$34K
- G Thomas-ClarkErie$6K
- Charles PerrottaErie$3K
- Brenton SongErie$3K
- David FigueroaErie$2K
- Prianka SinhaErie$1K
- Suzanne LucotCranberry Township$72K
- Dan UdreaWexford$51K
- Craig FeasterState College$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.